You are here: Home » Companies » News
Business Standard

US court rules in favour of Dr Reddy's, allows sale of generic Suboxone

According to market reports, suboxone had sales of around $1.86 billion in the US for the 12 months ended April

Press Trust of India  |  Hyderabad 

reddy, dr reddy's
Dr Reddy's laboratory

Dr Reddy's Laboratories Ltd Wednesday said a court in the US has given a ruling in favour of it in a patent infringement case filed by on selling a generic version of a sublingual film in the American market.

According to a press release issued by the city-based drug maker, the Court of Appeals for the Federal Circuit concluded that had not shown that it is likely to succeed on the merits of its infringement case.

It also said this decision vacates a District Court"s preliminary injunction that had prohibited Dr Reddy's from selling its generic version of (buprenorphine and naloxone).

Buprenorphine and naloxone are used to treat adults with opioid dependence or addiction.

As a result of today's ruling, Dr Reddy's will resume its launch activities as soon as it is permitted, it said.

According to market reports, had sales of around $1.86 billion in the US for the 12 months ended April.

A said, "We are pleased with the decision of the appellate court in Dr Reddy's favour, vacating the preliminary injunction that had prevented Dr Reddy's from bringing this important drug to the public.

We are committed to providing affordable and innovative medicines that address the unmet and under-met needs of patients around the world and in particular look forward to taking the lead in helping to fight "

In June, the (USFDA) approved Dr Reddy's Buprenorphine and Naloxone Sublingual Film, in four strengths including 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, for sale in the US market.

The product was launched immediately after approval, with sales and commercialisation activities halted as a result of a court-imposed temporary restraining order against Dr Reddy's.

The TRO did not include a prohibition on the commercial of the product.

First Published: Wed, November 21 2018. 10:15 IST
RECOMMENDED FOR YOU